Simvastatin exerts antiamnesic effect in Aβ25-35-injected mice

CNS Neuroscience and Therapeutics

Volumn 20, Issue 3, 2014, Pages 218-226

  Zhi, Wen Hong ^a,b   Zeng, Yan Ying ^b   Lu, Zi Hong ^a   Qu, Wei Jun ^a   Chen, Wei Xian ^b   Chen, Lei ^a   Chen, Ling ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

7 nicotinic acetylcholine receptor; amyloid peptide; Neuroprotection; Simvastatin; Synaptic plasticity

Indexed keywords

NEUROPROTECTION; SIMVASTATIN; SYNAPTIC PLASTICITY; Α7 NICOTINIC ACETYLCHOLINE RECEPTOR; Β-AMYLOID PEPTIDE;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; ANTICHOLESTEREMIC AGENTS; DISEASE MODELS, ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; MALE; MAP KINASE SIGNALING SYSTEM; MAZE LEARNING; MICE; MICE, INBRED ICR; ONCOGENE PROTEIN V-AKT; PATCH-CLAMP TECHNIQUES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PYRAMIDAL CELLS; SIMVASTATIN;

EID: 84894282705     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12190     Document Type: Article

References (39)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-344.
2. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004;5:347-360.
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-1427.
4. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J Neurol Neurosurg Psychiatry 2009;80:13-17.
5. Simons M, Schwärzler F, Lütjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-350.
6. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand 2006;185(Suppl):78-86.
7. Tong XK, Lecrux C, Rosa-Neto P, et al. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci 2012;32:4705-4715.
8. Li L, Cao D, Kim H, et al. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 2006;60:729-739.
9. Parri HR, Hernandez CM, Dineley KT. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol 2011;82:931-942.
10. Chen L, Wang H, Zhang Z, et al. DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid 25-35-injected mice through preventing the dysfunction of alpha7 nicotinic receptor. J Neurosci Res 2010;8:1784-1794.
11. Xiu J, Nordberg A, Shan KR, et al. Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. J Neurosci Res 2005;82:531-541.
12. Mozayan M, Lee TJ. Statins prevent cholinesterase inhibitor blockade of sympathetic alpha7-nAChR-mediated currents in rat superior cervical ganglion neurons. Am J Physiol Heart Circ Physiol 2007;293:H1737-H1744.
13. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, et al. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 1995;64:253-265.
14. Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 1996;706:181-193.
15. Yang R, Chen L, Wang H, et al. Anti-amnesic effect of neurosteroid PREGS in Aβ25-35-injected mice through σ1 receptor- and α7nAChR-mediated neuroprotection. Neuropharmacology 2012;63:1042-1050.
16. Kowall NW, McKee AC, Yankner BA. In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol Aging 1992;13:537-542.
17. Tsuji A, Saheki A, Tamai I, et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993;267:1085-1090.
18. Voisin EM, Ruthsatz M, Collins JM, et al. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul Toxicol Pharmacol 1990;12:107-116.
19. Johnson-Anuna LN, Eckert GP, Keller JH, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 2005;312:786-793.
20. Thelen KM, Rentsch KM, Gutteck U, et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 2006;316:1146-1152.
21. Cai W, Zhu Y, Furuya K, et al. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology 2008;55:127-138.
22. Dineley KT, Westerman M, Bui D, et al. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-4133.
23. Kihara T, Shimohama S, Sawada H, et al. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 2001;276:13541-13546.
24. Hirao K, Ohnishi T, Hirata Y, et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005;28:1014-1021.
25. Yoshida T, Ha-Kawa S, Yoshimura M, et al. Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease. Ann Nucl Med 2007;21:257-265.
26. Sánchez-Ferro A, Benito-León J, Mitchell AJ, et al. A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. Neuropsychiatr Dis Treat 2013;9:55-63.
27. Burghaus L, Schütz U, Krempel U, et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 2000;76:385-388.
28. Si ML, Long C, Yang DI, et al. Statins prevent beta-amyloid inhibition of sympathetic alpha7-nAChR-mediated nitrergic neurogenic dilation in porcine basilar arteries. J Cereb Blood Flow Metab 2005;25:1573-1585.
29. Barrantes FJ. Cholesterol effects on nicotinic acetylcholine receptor. J Neurochem 2007;103:72-80.
30. Xiu J, Nordberg A, Qi X, et al. Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. Neurochem Int 2006;49:459-465.
31. Kretz A, Schmeer C, Tausch S, et al. Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol Dis 2006;21:421-430.
32. Xu R, Chen J, Cong X, et al. Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2. J Cell Biochem 2008;103:256-269.
33. Fonseca AC, Proença T, Resende R, et al. Neuroprotective effects of statins in an in vitro model of Alzheimer's disease. J Alzheimers Dis 2009;17:503-517.
34. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
35. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001;76:1-10.
36. Opazo P, Watabe AM, Grant SG, et al. Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms. J Neurosci 2003;23:3679-3688.
37. Mans RA, Chowdhury N, Cao D, et al. Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience 2010;166:435-444.
38. Mans RA, McMahon LL, Li L. Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation. Neuroscience 2012;202:1-9.
39. Bate C, Williams A. Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Abeta(1-42). Neuropharmacology 2007;53:222-231.